COVID-19: the use of immunotherapy in metastatic lung cancer
The emergence of the novel coronavirus severe acute respiratory syndrome ([SARS]-CoV-2 or COVID-19) pandemic poses significant challenges for the treatment of all cancer patients, but in particular lung cancer patients where an increase in mortality has already been reported (7,8). Specifically, the...
Gespeichert in:
| Veröffentlicht in: | Immunotherapy 2020-06, Vol.12 (8), p.545-548 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 548 |
|---|---|
| container_issue | 8 |
| container_start_page | 545 |
| container_title | Immunotherapy |
| container_volume | 12 |
| creator | Davis, Alexander P Boyer, Michael Lee, Jenny H Kao, Steven C |
| description | The emergence of the novel coronavirus severe acute respiratory syndrome ([SARS]-CoV-2 or COVID-19) pandemic poses significant challenges for the treatment of all cancer patients, but in particular lung cancer patients where an increase in mortality has already been reported (7,8). Specifically, there was no increased incidence of hepatitis in patients with chronic viral hepatitis nor increased risk of immune reconstitution in patients with HIV infection receiving treatment with immunotherapy (14,15). While PD-1 therapy was not in use during recent viral outbreaks, we can look at their impact on lung cancer patients to gain insight into the specific challenges that COVID-19 will bring. With concerns about recent treatment for cancer increasing the risk of serious events with COVID-19, keeping the duration of treatment to an appropriate time would be important. [...]it may be reasonable to discuss stopping treatments in patients who have achieved a complete response or prolonged response for more than 2years during this COVID-19 pandemic. |
| doi_str_mv | 10.2217/imt-2020-0096 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7202359</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2501456807</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-9c5a5cd5a25148d80636de77a770a773f020a227a18884b63dd39e37bff56e703</originalsourceid><addsrcrecordid>eNp1kE1LwzAAhoMobk6PXqXguZrPphERZH4NBruoeAtZmm4ZazqTVNi_N2Nz6MFDyNeTNy8PAOcIXmGM-LVtYo4hhjmEojgAfcQZzDml5eF-TT564CSEBYQF5QU9Bj2CCRWMiz64HU7eRw85EjdZnJusCyZr68w2TefadODVap1ZlzUmqhBVtDpbdm6WaeW08afgqFbLYM528wC8PT2-Dl_y8eR5NLwf55oKEnOhmWK6YgozRMuqhAUpKsO54hymQepUX2HMFSrLkk4LUlVEGMKndc0KwyEZgLtt7qqbNqbSxkWvlnLlbaP8WrbKyr83zs7lrP2SPJkhTKSAy12Abz87E6JctJ13qbPEDCLKihLyROVbSvs2BG_q_Q8Iyo1smWTLjWy5kZ34i9-19vSP3QSILVB3sfMmaGuSNrndpRdWW2f-Cf8GLjKNNA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2501456807</pqid></control><display><type>article</type><title>COVID-19: the use of immunotherapy in metastatic lung cancer</title><source>MEDLINE</source><source>PubMed Central</source><creator>Davis, Alexander P ; Boyer, Michael ; Lee, Jenny H ; Kao, Steven C</creator><creatorcontrib>Davis, Alexander P ; Boyer, Michael ; Lee, Jenny H ; Kao, Steven C</creatorcontrib><description>The emergence of the novel coronavirus severe acute respiratory syndrome ([SARS]-CoV-2 or COVID-19) pandemic poses significant challenges for the treatment of all cancer patients, but in particular lung cancer patients where an increase in mortality has already been reported (7,8). Specifically, there was no increased incidence of hepatitis in patients with chronic viral hepatitis nor increased risk of immune reconstitution in patients with HIV infection receiving treatment with immunotherapy (14,15). While PD-1 therapy was not in use during recent viral outbreaks, we can look at their impact on lung cancer patients to gain insight into the specific challenges that COVID-19 will bring. With concerns about recent treatment for cancer increasing the risk of serious events with COVID-19, keeping the duration of treatment to an appropriate time would be important. [...]it may be reasonable to discuss stopping treatments in patients who have achieved a complete response or prolonged response for more than 2years during this COVID-19 pandemic.</description><identifier>ISSN: 1750-743X</identifier><identifier>EISSN: 1750-7448</identifier><identifier>DOI: 10.2217/imt-2020-0096</identifier><identifier>PMID: 32349579</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - complications ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - secondary ; Carcinoma, Non-Small-Cell Lung - therapy ; Coronavirus Infections - complications ; Coronavirus Infections - diagnosis ; Coronavirus Infections - epidemiology ; Coronavirus Infections - mortality ; Coronaviruses ; COVID-19 ; duration of therapy ; Dyspnea ; Encephalitis ; Epidemics ; Hepatitis ; HIV ; Human immunodeficiency virus ; Humans ; immune checkpoint inhibitors ; Immune reconstitution ; Immune system ; Immunotherapy ; Immunotherapy - adverse effects ; Immunotherapy - mortality ; Laboratories ; Lung cancer ; Lung Neoplasms - complications ; Lung Neoplasms - mortality ; Lung Neoplasms - secondary ; Lung Neoplasms - therapy ; Medical prognosis ; Metastases ; Metastasis ; Mortality ; Myocarditis ; Pandemics ; Patients ; PD-1 protein ; Pneumonia, Viral - complications ; Pneumonia, Viral - diagnosis ; Pneumonia, Viral - epidemiology ; Pneumonia, Viral - mortality ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Programmed Cell Death 1 Receptor - immunology ; Programmed Cell Death 1 Receptor - therapeutic use ; Risk Factors ; Severe acute respiratory syndrome ; Swine flu ; Vaccines</subject><ispartof>Immunotherapy, 2020-06, Vol.12 (8), p.545-548</ispartof><rights>2020 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Jun 2020</rights><rights>2020 Future Medicine Ltd 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-9c5a5cd5a25148d80636de77a770a773f020a227a18884b63dd39e37bff56e703</citedby><cites>FETCH-LOGICAL-c493t-9c5a5cd5a25148d80636de77a770a773f020a227a18884b63dd39e37bff56e703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202359/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202359/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32349579$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Davis, Alexander P</creatorcontrib><creatorcontrib>Boyer, Michael</creatorcontrib><creatorcontrib>Lee, Jenny H</creatorcontrib><creatorcontrib>Kao, Steven C</creatorcontrib><title>COVID-19: the use of immunotherapy in metastatic lung cancer</title><title>Immunotherapy</title><addtitle>Immunotherapy</addtitle><description>The emergence of the novel coronavirus severe acute respiratory syndrome ([SARS]-CoV-2 or COVID-19) pandemic poses significant challenges for the treatment of all cancer patients, but in particular lung cancer patients where an increase in mortality has already been reported (7,8). Specifically, there was no increased incidence of hepatitis in patients with chronic viral hepatitis nor increased risk of immune reconstitution in patients with HIV infection receiving treatment with immunotherapy (14,15). While PD-1 therapy was not in use during recent viral outbreaks, we can look at their impact on lung cancer patients to gain insight into the specific challenges that COVID-19 will bring. With concerns about recent treatment for cancer increasing the risk of serious events with COVID-19, keeping the duration of treatment to an appropriate time would be important. [...]it may be reasonable to discuss stopping treatments in patients who have achieved a complete response or prolonged response for more than 2years during this COVID-19 pandemic.</description><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - complications</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - secondary</subject><subject>Carcinoma, Non-Small-Cell Lung - therapy</subject><subject>Coronavirus Infections - complications</subject><subject>Coronavirus Infections - diagnosis</subject><subject>Coronavirus Infections - epidemiology</subject><subject>Coronavirus Infections - mortality</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>duration of therapy</subject><subject>Dyspnea</subject><subject>Encephalitis</subject><subject>Epidemics</subject><subject>Hepatitis</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>immune checkpoint inhibitors</subject><subject>Immune reconstitution</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Immunotherapy - adverse effects</subject><subject>Immunotherapy - mortality</subject><subject>Laboratories</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - complications</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - secondary</subject><subject>Lung Neoplasms - therapy</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>Myocarditis</subject><subject>Pandemics</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>Pneumonia, Viral - complications</subject><subject>Pneumonia, Viral - diagnosis</subject><subject>Pneumonia, Viral - epidemiology</subject><subject>Pneumonia, Viral - mortality</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><subject>Programmed Cell Death 1 Receptor - immunology</subject><subject>Programmed Cell Death 1 Receptor - therapeutic use</subject><subject>Risk Factors</subject><subject>Severe acute respiratory syndrome</subject><subject>Swine flu</subject><subject>Vaccines</subject><issn>1750-743X</issn><issn>1750-7448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kE1LwzAAhoMobk6PXqXguZrPphERZH4NBruoeAtZmm4ZazqTVNi_N2Nz6MFDyNeTNy8PAOcIXmGM-LVtYo4hhjmEojgAfcQZzDml5eF-TT564CSEBYQF5QU9Bj2CCRWMiz64HU7eRw85EjdZnJusCyZr68w2TefadODVap1ZlzUmqhBVtDpbdm6WaeW08afgqFbLYM528wC8PT2-Dl_y8eR5NLwf55oKEnOhmWK6YgozRMuqhAUpKsO54hymQepUX2HMFSrLkk4LUlVEGMKndc0KwyEZgLtt7qqbNqbSxkWvlnLlbaP8WrbKyr83zs7lrP2SPJkhTKSAy12Abz87E6JctJ13qbPEDCLKihLyROVbSvs2BG_q_Q8Iyo1smWTLjWy5kZ34i9-19vSP3QSILVB3sfMmaGuSNrndpRdWW2f-Cf8GLjKNNA</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Davis, Alexander P</creator><creator>Boyer, Michael</creator><creator>Lee, Jenny H</creator><creator>Kao, Steven C</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20200601</creationdate><title>COVID-19: the use of immunotherapy in metastatic lung cancer</title><author>Davis, Alexander P ; Boyer, Michael ; Lee, Jenny H ; Kao, Steven C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-9c5a5cd5a25148d80636de77a770a773f020a227a18884b63dd39e37bff56e703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - complications</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - secondary</topic><topic>Carcinoma, Non-Small-Cell Lung - therapy</topic><topic>Coronavirus Infections - complications</topic><topic>Coronavirus Infections - diagnosis</topic><topic>Coronavirus Infections - epidemiology</topic><topic>Coronavirus Infections - mortality</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>duration of therapy</topic><topic>Dyspnea</topic><topic>Encephalitis</topic><topic>Epidemics</topic><topic>Hepatitis</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>immune checkpoint inhibitors</topic><topic>Immune reconstitution</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Immunotherapy - adverse effects</topic><topic>Immunotherapy - mortality</topic><topic>Laboratories</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - complications</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - secondary</topic><topic>Lung Neoplasms - therapy</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>Myocarditis</topic><topic>Pandemics</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>Pneumonia, Viral - complications</topic><topic>Pneumonia, Viral - diagnosis</topic><topic>Pneumonia, Viral - epidemiology</topic><topic>Pneumonia, Viral - mortality</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><topic>Programmed Cell Death 1 Receptor - immunology</topic><topic>Programmed Cell Death 1 Receptor - therapeutic use</topic><topic>Risk Factors</topic><topic>Severe acute respiratory syndrome</topic><topic>Swine flu</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Davis, Alexander P</creatorcontrib><creatorcontrib>Boyer, Michael</creatorcontrib><creatorcontrib>Lee, Jenny H</creatorcontrib><creatorcontrib>Kao, Steven C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Davis, Alexander P</au><au>Boyer, Michael</au><au>Lee, Jenny H</au><au>Kao, Steven C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19: the use of immunotherapy in metastatic lung cancer</atitle><jtitle>Immunotherapy</jtitle><addtitle>Immunotherapy</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>12</volume><issue>8</issue><spage>545</spage><epage>548</epage><pages>545-548</pages><issn>1750-743X</issn><eissn>1750-7448</eissn><abstract>The emergence of the novel coronavirus severe acute respiratory syndrome ([SARS]-CoV-2 or COVID-19) pandemic poses significant challenges for the treatment of all cancer patients, but in particular lung cancer patients where an increase in mortality has already been reported (7,8). Specifically, there was no increased incidence of hepatitis in patients with chronic viral hepatitis nor increased risk of immune reconstitution in patients with HIV infection receiving treatment with immunotherapy (14,15). While PD-1 therapy was not in use during recent viral outbreaks, we can look at their impact on lung cancer patients to gain insight into the specific challenges that COVID-19 will bring. With concerns about recent treatment for cancer increasing the risk of serious events with COVID-19, keeping the duration of treatment to an appropriate time would be important. [...]it may be reasonable to discuss stopping treatments in patients who have achieved a complete response or prolonged response for more than 2years during this COVID-19 pandemic.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>32349579</pmid><doi>10.2217/imt-2020-0096</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1750-743X |
| ispartof | Immunotherapy, 2020-06, Vol.12 (8), p.545-548 |
| issn | 1750-743X 1750-7448 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7202359 |
| source | MEDLINE; PubMed Central |
| subjects | Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Cancer therapies Carcinoma, Non-Small-Cell Lung - complications Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - secondary Carcinoma, Non-Small-Cell Lung - therapy Coronavirus Infections - complications Coronavirus Infections - diagnosis Coronavirus Infections - epidemiology Coronavirus Infections - mortality Coronaviruses COVID-19 duration of therapy Dyspnea Encephalitis Epidemics Hepatitis HIV Human immunodeficiency virus Humans immune checkpoint inhibitors Immune reconstitution Immune system Immunotherapy Immunotherapy - adverse effects Immunotherapy - mortality Laboratories Lung cancer Lung Neoplasms - complications Lung Neoplasms - mortality Lung Neoplasms - secondary Lung Neoplasms - therapy Medical prognosis Metastases Metastasis Mortality Myocarditis Pandemics Patients PD-1 protein Pneumonia, Viral - complications Pneumonia, Viral - diagnosis Pneumonia, Viral - epidemiology Pneumonia, Viral - mortality Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - immunology Programmed Cell Death 1 Receptor - therapeutic use Risk Factors Severe acute respiratory syndrome Swine flu Vaccines |
| title | COVID-19: the use of immunotherapy in metastatic lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A27%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19:%20the%20use%20of%20immunotherapy%20in%20metastatic%20lung%20cancer&rft.jtitle=Immunotherapy&rft.au=Davis,%20Alexander%20P&rft.date=2020-06-01&rft.volume=12&rft.issue=8&rft.spage=545&rft.epage=548&rft.pages=545-548&rft.issn=1750-743X&rft.eissn=1750-7448&rft_id=info:doi/10.2217/imt-2020-0096&rft_dat=%3Cproquest_pubme%3E2501456807%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2501456807&rft_id=info:pmid/32349579&rfr_iscdi=true |